<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03958344</url>
  </required_header>
  <id_info>
    <org_study_id>IR.IUMS.REC.1397.1202</org_study_id>
    <nct_id>NCT03958344</nct_id>
  </id_info>
  <brief_title>Intraorbital Injection Versus Oral Steroid in Anterior Idiopathic Orbital Inflammation</brief_title>
  <official_title>Intraorbital Injection Versus Oral Steroid in Patients With Anterior Idiopathic Orbital Inflammation: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Iran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter randomised double-arm clinical trial, to compare safety and efficacy of oral
      versus intralesional injection of steroid in a group of patients suffering from idiopathic
      orbital inflammation is designed. Outcome measures include number of recurrences, duration of
      remission, and side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Expected to be finished in 3 years, patient enrollment includes 59 patient in each arm of the
      study. Inclusion criteria consist of clinical and/or imaging evidence of dacryoadenitis with
      or without adjacent rectus muscles (superior and inferior recti) myositis. Patients meeting
      following conditions will be excluded:

        1. Age &lt; 15 years

        2. Diabetes mellitus

        3. Collagen Vascular Diseases

        4. Vasculitides

        5. Biopsy of lacrimal gland denoting a specific diagnosis (i.e. the term &quot;idiopathic&quot; does
           not apply)

        6. Glaucoma

        7. Patients who have lost one eye

        8. Bilateral disease

        9. Abnormal thyroid-stimulating hormone

      Outcome measures include number of recurrences, duration of remission, and side effects.

      Patient allocation will be based on blocks of 4. Each patient will undergo lacrimal gland
      biopsy and subsequently will be allocated to one arm of the study according to a
      predetermined randomization sequence (balanced block of four). Outcome measures will be
      recorded in 0, 3 and 6 months after patient enrollment.

      Patients in oral steroid group will receive 1 mg/kg/day of Prednisolone, tapered in 3 months
      (based on a detailed table).

      Patients in injection group will receive 1 shot of 1 mL (20 mg Triamcinolone + 3 mg
      Betamethason) into the lacrimal gland.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized parallel double arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence number</measure>
    <time_frame>up to 6 months</time_frame>
    <description>frequency of occurrence of clinical condition showing signs of inflammation recurrence, during or after cessation of steroid therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence time</measure>
    <time_frame>up to 6 months</time_frame>
    <description>mean time of occurrence of clinical condition showing signs of inflammation recurrence, during or after cessation of steroid therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Effect</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Any significant ocular or systemic side effect reported by the patient or found in examination sessions</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Orbital Pseudotumor</condition>
  <arm_group>
    <arm_group_label>Intraorbital injection of steroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mL of steroid will be ready for each injection session:
1 mL Triamcinolone (40 mg) + 1 mL Betamethasone (6 mg) = 2 mL
For Dacryoadenitis without myositis , 1 mL of this compound will be injected at lacrimal gland through 1 site of injection.
For Dacryoadenitis plus 1 rectus muscles myositis 1 mL of this compound will be injected at lacrimal gland and 0.5 mL of this compound will be injected at the rectus muscle through 2 separate sites of injection.
For Dacryoadenitis plus 2 rectus muscles myositis 1 mL of this compound will be injected at lacrimal gland and 0.5 mL of this compound will be injected at either recti muscles through 3 separate sites of injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each patient will receive oral Prednisolone, 1 mg/kg, for 5-7 days, followed by tapered dose in 12 weeks (according to a pre-defined table of oral administration dose).
Daily Omeprazole 40mg p.o and daily Calcium Supplement will also be recommended to avoid complications.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Oral Tablet</description>
    <arm_group_label>Oral Steroid</arm_group_label>
    <other_name>Oral Prednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone + Betamethason</intervention_name>
    <description>A compound long acting and short acting injectable steroid</description>
    <arm_group_label>Intraorbital injection of steroid</arm_group_label>
    <other_name>Injectable Steroid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dacryoadenitis based on clinical findings and/or imaging with and without adjacent
             recti muscle myositis

        Exclusion Criteria:

          -  Abnormal thyroid-stimulating hormone

          -  Systemic Vasculitides

          -  Bilateral Orbital Inflammation

          -  Collagen Vascular Diseases

          -  One Seeing Eye

          -  Glaucoma

          -  Diabetes Mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohsen B Kashkouli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohsen B Kashkouli, MD</last_name>
    <phone>00989121777003</phone>
    <email>mkashkouli2@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nasser Karimi, MD</last_name>
    <phone>+989123272376</phone>
    <email>karimi.na@iums.ac.ir</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Iran University of Medical Sciences</name>
      <address>
        <city>TehrƒÅn</city>
        <state>Tehran</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Swamy BN, McCluskey P, Nemet A, Crouch R, Martin P, Benger R, Ghabriel R, Wakefield D. Idiopathic orbital inflammatory syndrome: clinical features and treatment outcomes. Br J Ophthalmol. 2007 Dec;91(12):1667-70. Epub 2007 Jul 9.</citation>
    <PMID>17620331</PMID>
  </reference>
  <reference>
    <citation>Bijlsma WR, Paridaens D, Kalmann R. Treatment of severe idiopathic orbital inflammation with intravenous methylprednisolone. Br J Ophthalmol. 2011 Aug;95(8):1068-71. doi: 10.1136/bjo.2010.195552. Epub 2011 Feb 24.</citation>
    <PMID>21349945</PMID>
  </reference>
  <results_reference>
    <citation>El Nasser A Mohammad A. Local steroid injection for management of different types of acute idiopathic orbital inflammation: an 8-year study. Ophthalmic Plast Reconstr Surg. 2013 Jul-Aug;29(4):286-9. doi: 10.1097/IOP.0b013e318293750c.</citation>
    <PMID>23839634</PMID>
  </results_reference>
  <results_reference>
    <citation>Leibovitch I, Prabhakaran VC, Davis G, Selva D. Intraorbital injection of triamcinolone acetonide in patients with idiopathic orbital inflammation. Arch Ophthalmol. 2007 Dec;125(12):1647-51.</citation>
    <PMID>18071116</PMID>
  </results_reference>
  <results_reference>
    <citation>Reggie S, Neimkin M, Holds J. Intralesional corticosteroid injections as treatment for non-infectious orbital inflammation. Orbit. 2018 Feb;37(1):41-47. doi: 10.1080/01676830.2017.1353110. Epub 2017 Sep 5.</citation>
    <PMID>28872378</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Orbital Pseudotumor</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

